1.
Statins as antithrombotic drugs.(Special Report)(Drug overview)
by Violi, Francesco
Circulation, Jan 15, 2013, Vol.127(2), p.251-257
2.
Association Between Use of Statin Medication and Weight Change in Older Men.(Report)
by Strandberg, Timo E
Journal of the American Geriatrics Society, August, 2012, Vol.60(8), p.1588(3)
3.
Midlife Characteristics of Older Men Using Statins.(Report)
by Strandberg, Timo E.
Journal of the American Geriatrics Society, May, 2013, Vol.61(5), p.831(2)
4.
Additional insights on how best to utilize statins.(LETTERS)(Letter to the editor)
by Feeman, William E. , Jr.
Journal of Family Practice, March, 2014, Vol.63(3), p.128(1)
5.
How to Control Residual Risk During the Statin Era?
by Koh, Kwang
Journal of the American College of Cardiology, Oct 20, 2015, Vol.66(16), p.1848
6.
GW26-e2366 Changes in Carotid Plaque Lipid Content in Subjects Who Continued and Discontinued Statin Therapy
by Du, Ruixue
Journal of the American College of Cardiology, Oct 20, 2015, Vol.66(16), p.C229
7.
Frequency of Development of Connective Tissue Disease in Statin-Users Versus Nonusers
by Schmidt, Thomas
The American Journal of Cardiology, Sep 15, 2013, Vol.112(6), p.883
8.
Silencing p110[beta] prevents rapid depletion of nuclear pAkt
by Ye, Zhi - Wei
Biochemical and Biophysical Research Communications, Dec 2, 2011, Vol.415(4), p.613(6)
9.
Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents
by Mallinson, Joanne E.
Journal of Physiology, Dec, 2012, Vol.590, p.6389(14)
10.
Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents
by Mallinson, Joanne E.
Journal of Physiology, Dec, 2012, Vol.590, p.6389(14)
11.
Regarding long-term statin therapy: Are we trading stronger hearts for weaker brains?
by Goldstein, Mark R.
Medical Hypotheses, Sept, 2014, Vol.83(3), p.346(6)
12.
Potential role of statins for the management of immune reconstitution syndrome.(Disease/Disorder overview)(Report)
by Sun, Hsin - Yun
Medical Hypotheses, March, 2011, Vol.76(3), p.307(4)
13.
Statins and myopathies
by Hilton-Jones, D.
Journal of the Neurological Sciences, Oct 15, 2015, Vol.357, p.e476
14.
Statins discontinuation in compliant chronic users induces atherothrombotic profile despite baseline clinical setting and treatments
by Puccetti, Luca
International Journal of Cardiology, 2011, Vol.153(3), pp.328-329
15.
The role of media on statin adherence
by Kocas, Cuneyt
International Journal of Cardiology, Dec 15, 2015, Vol.201, p.139
16.
Inflammatory rebound phenomenon after abrupt withdrawal of statin is a mature point of view but not hypotheses
by Li, Jian - Jun
International Journal of Cardiology, August 18, 2011, Vol.151(1), p.120
17.
Effect of Cilostazol on The Pharmacodynamics of Cyp3a and Non-Cyp3a-Dependent Statins
by Jung, Ja
Clinical Therapeutics, Aug 2015, Vol.37(8), pp.e23-e24
18.
Generic Use In Statin Sales In The Community of Thessaloniki, Greece
by Papaioannidou, P.
Clinical Therapeutics, 2015, Vol.37(8), pp.e148-e149
19.
Contour plot assessment of existing meta-analyses confirms robust association of statin use and acute kidney injury risk
by Chevance, Aurélie
Journal of Clinical Epidemiology, October 2015, Vol.68(10), pp.1138-1143
20.
DOES PLAQUE BURDEN PREDICT VASCULAR RESPONSE TO STATIN THERAPY? A COMBINED OCT AND IVUS STUDY
by Soeda, Tsunenari
Journal of the American College of Cardiology, Mar 17, 2015, Vol.65(10), p.A1574
